Yubo International Biotech Ltd

Market Cap $5.33M
Debt $NaN
Cash $8.03K
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$2.15M
EBIT	-$1.93M
ROA	-117%
Equity	-$3.04M
Growth Stability	1
PE	-2.48
PB	-1.75
P/S	206.88
Price/Cash	0
Net Margins	-47K%
Gross Margins	80%
Op. Margins	-7K%
Sales Growth YoY	-100%
Sales CAGR	-1%
Equity CAGR	0%
Earnings Growth YoY	-10K%

Earnings Growth QoQ	4%
Sales CAGR 5Y	-23%
Equity CAGR 5Y	1%
Earnings CAGR 3Y	-41%
Sales CAGR 3Y	-41%
Market Cap	$5.33M
Revenue	$25.77K
Assets	$1.65M
Cash	$8.03K
Shares Outstanding	119.82M
Working Capital	-3.77M
Current Ratio	0.16
Gross Profit	$20.72K
Equity Growth QoQ	26%
Equity Growth YoY	176%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.

SEC Filings

Direct access to Yubo International Biotech Ltd (YBGJ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Yubo International Biotech Ltd compare to its competitors?

Not enough data to generate a comparison chart between Yubo International Biotech Ltd and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Yubo International Biotech Ltd compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Yubo International Biotech Ltd Discounted Cash Flow

Fully customizable DCF calculator online for Yubo International Biotech Ltd.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	02/2015	02/2016	02/2017	02/2018	02/2019	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-124%	-1K%	-198%	-47K%
ROA	-	-450%	-	-	-1K%	-34%	-51%	-72%	-117%
ROE	-	10%	16%	9%	9%	-106%	-83%	65%	-

Bad Net Margins (-46.7K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	02/2015	02/2016	02/2017	02/2018	02/2019	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	02/2015	02/2016	02/2017	02/2018	02/2019	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-92%	480%	-23%
Earnings YoY growth	-	12%	72%	-36%	3%	942%	-22%	-1%	-
Equity YoY growth	-	12%	9%	10%	10%	-187%	0%	-227%	1%
FCF YoY growth	-	-	-	-	-	-	-104%	-	-